OTIC

Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

Otonomy, Inc. (OTIC) CEO David Weber on Q1 2021 Results - Earnings Call Transcript

Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update

Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Otonomy Announces Pricing of $30.1 Million Public Offering